Stereotactic Ablative Radiotherapy May Be Feasible for Non-Small Cell Lung Cancer
the Cancer Therapy Advisor take:
Stereotactic ablative radiotherapy (SABR) could be an option for treating patients with operable stage I non-small cell lung cancer (NSCLC), a recent study published online first in the journal The Lancet Oncology has shown.
For the study, researchers conducted a pooled analysis of the STARS and ROSEL studies, which closed early due to slow accrual. In the intention-to-treat population, 58 patients with clinical T1-2a, N0M0, operable NSCLC were enrolled and randomly assigned 1:1 to SABR or lobectomy with mediastinal lymph node dissection or sampling.
Results showed that estimated overall survival at 3 years was 95% (95% CI: 85-100) in the SABR group versus 79% (95% CI: 64-97) in the lobectomy group (HR = 0.14; 95% CI: 0.017-1.190; log-rank P = 0.037). Researchers found that recurrence-free survival at 3 years was 86% (95% CI: 74-100) and 80% (95% CI: 65-97) in the SABR and surgery groups, respectively (HR = 0.69; 95% CI: 0.21-2.29; log-rank P = 0.54).
The researchers note that because of the small patient sample size and median follow-up of only 40.2 months in the SABR group and 35.4 months in the surgery group, additional randomized studies comparing the two in patients with operable NSCLC are needed.
Stereotactic ablative radiotherapy could be an option for treating patients with operable stage I NSCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia